Tag: Competition

Displaying 121 - 140 of 2219 results.

Pages

Ten years ago this month, the FTC and DOJ issued the Commentary on the Horizontal Merger Guidelines.
Testifying on behalf of the Federal Trade Commission before the U.S. Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights, Chairwoman Edith Ramirez outlined how effective antitrust enforcement benefits both consumers and businesses by preventing mergers and business...
The FTC issued an administrative complaint alleging that the proposed merger of Advocate Health Care Network and NorthShore University HealthSystem will create the largest hospital system in the North Shore area of Chicago.  According to the complaint, the combined entity would...
Drug manufacturer Hikma Pharmaceuticals PLC agreed to sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that its proposed $2 billion acquisition of Roxane would likely be anticompetitive...
There is a basic but important difference between antitrust cases brought by the government and those brought by private parties: All plaintiffs, including government enforcers like the FTC, must prove an antitrust violation, which requires showing harm to competition. But private...
Drug manufacturer Hikma Pharmaceuticals PLC will sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that Hikma’s proposed $2 billion acquisition of Roxane would likely be anticompetitive.
The FTC issued an administrative complaint and authorized staff to seek a preliminary injunction to enjoin the transaction pending the results of the administrative proceeding, charging that Staples, Inc.’s proposed $6.3 billion acquisition of Office Depot, Inc. would  significantly...
The Federal Trade Commission has approved a modified final order settling charges that Mylan N.V.’s proposed hostile takeover of Perrigo Company plc would harm competition. Because Mylan failed to obtain the required threshold of Perrigo shares to succeed in its unsolicited offer, Mylan has...
From: Walsh, Kathryn E. [mailto:kwalsh@ftc.gov]Sent: Friday, February 19, 2016 11:17 AMTo: [REDACTED]Subject: RE: Natural Person
Generic drug marketer Hikma Pharmaceuticals PLC agreed to divest its rights and interests in five generic injectable pharmaceuticals to settle charges that its $5 million acquisition of the rights to various drug products and related assets from Ben Venue Laboratories, Inc. would...
From: Walsh, Kathryn E.Sent: Friday, February 19, 2016 10:50 AMTo: [REDACTED]Cc: Gillis, Diana L.; Jones, Robert L.Subject: RE: Bankruptcy reorganization - exchange of debt for equity
The Federal Trade Commission will require generic drug marketer Hikma Pharmaceuticals PLC to divest its rights and interests in five generic injectable pharmaceuticals, as part of a settlement resolving charges that Hikma’s $5 million acquisition of the rights to various drug products and related...
Generic drug manufacturers Lupin Ltd. and Gavis Pharmaceuticals LLC agreed to sell the rights and assets for two generic drugs, in order to settle FTC charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive.The merger would have combined two of...
Generic drug manufacturers Lupin Ltd. and Gavis Pharmaceuticals LLC will sell the rights and assets for two generic drugs, one used to treat bacterial infections and the other to treat ulcerative colitis, in order to settle FTC charges that Lupin’s proposed $850 million acquisition of Gavis would...
In response to a request by Massachusetts State Representative Bradley H. Jones, the Federal Trade Commission and the Department of Justice’s Antitrust Division have submitted a statement encouraging the Massachusetts legislature to consider expanding the services that optometrists can provide to...
From: Walsh, Kathryn E.Sent: Friday, January 15, 2016 11:22 AMTo: [REDACTED]Cc: Whitehead, Nora; Pope, Susan H.Subject: RE: Insurance Ordinary Course Exemption under 7A(c)(1) and/or 802.1
The Federal Trade Commission filed an amicus brief in the U.S. Court of Appeals for the First Circuit urging the court to correct the district court’s holding that a plaintiff must prove an injury-in-fact in order to establish an antitrust violation.
From: Walsh, Kathryn E.Sent: Friday, January 15, 2016 10:56 AMTo: [REDACTED]Cc: [REDACTED]; Whitehead, NoraSubject: RE: Follow up question about foreign services under Rule 802.51 (Informal Staff Interpretation 0502013) [REDACTED] When we wrote #152, we had in mind the entities that...

Pages